BRPI0513819A - inibidores de hsp90 - Google Patents

inibidores de hsp90

Info

Publication number
BRPI0513819A
BRPI0513819A BRPI0513819-1A BRPI0513819A BRPI0513819A BR PI0513819 A BRPI0513819 A BR PI0513819A BR PI0513819 A BRPI0513819 A BR PI0513819A BR PI0513819 A BRPI0513819 A BR PI0513819A
Authority
BR
Brazil
Prior art keywords
compounds
hsp90 inhibitors
indazol
novel
treatment
Prior art date
Application number
BRPI0513819-1A
Other languages
English (en)
Inventor
Patrick Chene
Andreas Floersheimer
Pascal Furet
Joseph Schoepfer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0513819A publication Critical patent/BRPI0513819A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INIBIDORES DE HSP90. A presente invenção refere-se ao uso de compostos 1H-indazol-6-ol e sais dos mesmos no tratamento de doenças proliferativas e para a fabricação de preparações farmacêuticas para o tratamento das ditas doenças, preparações farmacêuticas compreendendo compostos 1H-indazol-6-ol, novos compostos 1H-indazol-6-ol, e um processo para a preparação de novos compostos 1H-indazol-6-ol.
BRPI0513819-1A 2004-07-27 2005-07-26 inibidores de hsp90 BRPI0513819A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59132904P 2004-07-27 2004-07-27
PCT/EP2005/008119 WO2006010595A1 (en) 2004-07-27 2005-07-26 Inhibitors of hsp90

Publications (1)

Publication Number Publication Date
BRPI0513819A true BRPI0513819A (pt) 2008-05-20

Family

ID=35058416

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513819-1A BRPI0513819A (pt) 2004-07-27 2005-07-26 inibidores de hsp90

Country Status (11)

Country Link
US (1) US20090039811A1 (pt)
EP (1) EP1773327A1 (pt)
JP (1) JP2008508218A (pt)
KR (1) KR20070038565A (pt)
CN (1) CN101027053A (pt)
AU (1) AU2005266494B2 (pt)
BR (1) BRPI0513819A (pt)
CA (1) CA2574313A1 (pt)
MX (1) MX2007001132A (pt)
RU (1) RU2007106929A (pt)
WO (1) WO2006010595A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267087A1 (en) * 2004-04-28 2005-12-01 Vassiliki Poulaki Inflammatory eye disease
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US20070027150A1 (en) * 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones
US20080200488A1 (en) * 2005-08-11 2008-08-21 Manley Paul W Combinations Comprising a Protein Kinase Inhibitor Being a Pyrimidylaminobenzamide Compound and a Hsp90 Inhibitor Such as 17-Aag
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
TW200901960A (en) * 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
WO2011116181A1 (en) * 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
WO2010082813A1 (en) * 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
US8292879B2 (en) * 2009-04-17 2012-10-23 Domain Surgical, Inc. Method of treatment with adjustable ferromagnetic coated conductor thermal surgical tool
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
WO2012148550A1 (en) * 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
KR101641829B1 (ko) 2015-04-23 2016-07-22 계명대학교 산학협력단 Hsp90 억제 활성을 갖는 신규한 티에노피리딘 화합물 및 이의 의학적 용도
KR102010274B1 (ko) 2016-01-29 2019-08-13 계명대학교 산학협력단 Ｈｓｐ９０ 억제 활성을 갖는 신규 벤즈아미드 화합물 또는 이의 약제학적으로 허용가능한 염 및 이의 의학적 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1266763B (de) * 1965-07-27 1968-04-25 Kalle Ag Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten
CA2244831A1 (en) * 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
NZ535349A (en) * 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting

Also Published As

Publication number Publication date
CN101027053A (zh) 2007-08-29
AU2005266494B2 (en) 2009-09-10
AU2005266494A1 (en) 2006-02-02
EP1773327A1 (en) 2007-04-18
JP2008508218A (ja) 2008-03-21
KR20070038565A (ko) 2007-04-10
RU2007106929A (ru) 2008-09-10
CA2574313A1 (en) 2006-02-02
US20090039811A1 (en) 2009-02-12
MX2007001132A (es) 2007-03-15
WO2006010595A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
BRPI0509655A (pt) uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina
BRPI0608297A2 (pt) composições de lipossomos
BRPI0416796A (pt) compostos orgánicos
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0512237A (pt) cis-imidazolinas
BR112013020005A2 (pt) peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0820622A2 (pt) Compostos derivados de aminotiazol, processo para a sua preparação, composição farmacêutica que os compreende, uso dos mesmos e métodos para o tratamento e/ou profilaxia de diabetes e outras enfermidades
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0815493A2 (pt) Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
BRPI0510084A (pt) benzoxazina para tratamento de doenças do trato respiratório

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.